Article Details

Galectin Therapeutics (NASDAQ:GALT) Earns Sell Rating from Analysts at StockNews.com

Retrieved on: 2022-03-14 17:09:20

Tags for this article:

Click the tags to see associated articles and topics

Galectin Therapeutics (NASDAQ:GALT) Earns Sell Rating from Analysts at StockNews.com. View article details on hiswai:

Excerpt

Millennium Management LLC now owns 405,601 shares of the company's stock valued at $840,000 after acquiring an additional 55,265 shares during the ...

Article found on: www.marketbeat.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up